Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents

Executive Summary

Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.

You may also be interested in...



FTC Competition Hearings: PhRMA, Former Rep. Waxman Advocate Focus On PBMs

FTC is assessing possible changes to competition and consumer protection enforcement law and policy, with a hearing on Innovation and IP Policy set for Oct. 23-24.

Sen. Hatch, Biopharma Industry Champion, Ready To Hang Up His Gloves

Hatch had a hand in major bipartisan legislation creating markets for generic drugs, orphan drugs, biosimilars, and dietary supplements.

Sen. Hatch, Biopharma Industry Champion, Ready To Hang Up His Gloves

Hatch had a hand in major bipartisan legislation creating markets for generic drugs, orphan drugs, biosimilars, and dietary supplements.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS055895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel